Mirogabalin is non-inferior or superior to pregabalin in reducing pain in Asian patients with fibromyalgia
This is a protocol for a prospective, multicentre, randomised, open-label, blinded endpoint (PROBE) trial comparing mirogabalin with pregabalin in 674 adult fibromyalgia patients with moderate-to-severe pain. The primary outcome is the proportion of patients achieving at least 50% pain reduction at 12 weeks. The study aims to provide evidence on mirogabalin's efficacy and safety in an Asian fibromyalgia population, where direct comparisons are lacking.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Mirogabalin is non-inferior or superior to pregabalin in reducing pain in Asian patients with fibromyalgia The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Mirogabalin is non-inferior or superior to pregabalin in reducing pain in Asian patients with fibromyalgia
This conclusion is most relevant to: Adults over 18 years diagnosed with fibromyalgia according to 2016 revisions to 2010/2011 criteria, with moderate-to-severe pain, from five Chinese hospitals.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy and safety of mirogabalin in patients with fibromyalgia: protocol for a multicentre, Prospective, Randomised, Open-label, Blinded Endpoint (PROBE) study. (BMJ open, 2026) —
How It Works
The proposed biological pathway:
- ▸Mirogabalin binds to α2δ subunits of voltage-gated calcium channels
- ▸This binding reduces calcium influx and neurotransmitter release
- ▸Modulation of pain signaling pathways leads to analgesic effects
- ▸Result: Potential pain reduction in fibromyalgia patients
Who Might Benefit
Evidence fit by population:
- ▸Adults over 18 years diagnosed with fibromyalgia according to 2016 revisions to 2010/2011 criteria, with moderate-to-severe pain, from five Chinese hospitals
Recommended Dose
Individualised dose titration based on response and tolerability (exact doses not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Open-label design may introduce bias despite blinded endpoint assessment
- ▸No results yet; protocol paper only, so efficacy and safety claims are not yet confirmed
- ▸Limited to Asian population, may not generalise to other ethnic groups
Frequently Asked Questions
What is the primary outcome of this mirogabalin trial?▼
The primary outcome is the proportion of patients achieving at least 50% pain reduction at 12 weeks.
How many patients are enrolled in this study?▼
674 qualified patients with moderate-to-severe fibromyalgia are randomly assigned to either mirogabalin or pregabalin in a 1:1 ratio.
What is the study design?▼
It is a prospective, multicentre, randomised, open-label, blinded endpoint (PROBE) trial.
Why is this study needed?▼
There is limited data on mirogabalin for fibromyalgia, and no direct comparison with pregabalin in an Asian fibromyalgia population.
References
- 1.Liu M, Li Y, Yao X, Liang Y, Mao P, Huang Y, Zhang C, Li Y, Li C, Ma K, Li S, Zhang D, Luo F, Fan B. “Efficacy and safety of mirogabalin in patients with fibromyalgia: protocol for a multicentre, Prospective, Randomised, Open-label, Blinded Endpoint (PROBE) study..” BMJ open, 2026. PMID: 42642082 DOI: 10.1136/bmjopen-2025-110911